Maintaining Our Roche and Chugai FVEs Following Strong Hemophilia Data
Roche and Chugai announced positive data for hemophilia drug emicizumab in two important clinical trials, and we’re maintaining our CHF 318/$41.50 fair value estimate for Roche and JPY 3,780 per share fair value estimate for Chugai. We believe that Roche’s branded drug and diagnostic segments warrant a wide moat, and strong data from Chugai-discovered emicizumab supports Chugai’s narrow moat despite pricing pressure in Japan. Roche shares look undervalued, and we see positive catalysts for the r...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.